Redeye: Stille - A Resilient Investment Case
Redeye returns with an updated view of Stille following the Q3 2022 report. We make minor adjustments to our forecasts and WACC, which slightly lowers our fair value range. Considering this, we see Stille being valued at a discount compared to our DCF-value and peers.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.